The "Nasopharyngeal Cancer - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
This "Nasopharyngeal Cancer - Pipeline Insight, 2021," report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Nasopharyngeal Cancer pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The companies and academics are working to assess challenges and seek opportunities that could influence R&D. Nasopharyngeal Cancer The therapies under development are focused on novel approaches to treat/improve Nasopharyngeal Cancer.
NASOPHARYNGEAL CANCER Emerging Drugs Chapters
This segment of the Nasopharyngeal Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Nasopharyngeal Cancer Emerging Drugs
Sintililimab: Innovent Biologics (Suzhou) Co. Ltd.
Sintilimab, a highly selective fully human IgG4 monoclonal antibody, blocks the binding site of programmed cell death protein 1 (PD-1), thereby, inhibiting the interaction between PD-1 and its ligands (PD-L1/2) to restore the endogenous anti-tumor T cell responses. The clinical trials for sintilimab are being evaluated for the treatment of Nasopharyngeal Neoplasms in phase III stage of development.
Tislelizumab (BGB-A317) is a humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to Fc?R on macrophages. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. It is being studied in phase III stage of development for the treatment of Recurrent or Metastatic Nasopharyngeal Cancer.
Tabelecleucel: Atara Biotherapeutics Inc.
Tabelecleucel, tab-cel is an off-the-shelf, allogeneic T-cell immunotherapy in phase I/II studies for the treatment of nasopharyngeal carcinoma.
PDR001: Novartis Pharmaceuticals
PDR001 (anti-PD-1) is an investigational immunotherapy being developed by Novartis to treat both solid tumors and lymphomas. PDR001 is a type of immunotherapy, it acts by activating the body's own immune system to recognize and fight cancer cells. The drug is being studied in phase II stage of development for the treatment of Nasopharyngeal cancer.
Nasopharyngeal Cancer: Therapeutic Assessment
This segment of the report provides insights about the different NASOPHARYNGEAL CANCER drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Nasopharyngeal Cancer
There are approx. 10+ key companies which are developing the therapies for NASOPHARYNGEAL CANCER. The companies which have their Nasopharyngeal Cancer drug candidates in the most advanced stage, i.e. phase III include, Innovent Biologics.
This report covers around 10+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Nasopharyngeal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Nasopharyngeal Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Nasopharyngeal Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Nasopharyngeal Cancer drugs.
NASOPHARYNGEAL CANCER Report Insights
Nasopharyngeal Cancer Pipeline Analysis
Impact of Drugs
NASOPHARYNGEAL CANCER Report Assessment
Pipeline Product Profiles
Inactive drugs assessment
Key Questions Answered
How many companies are developing Nasopharyngeal Cancer drugs?
How many Nasopharyngeal Cancer drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Nasopharyngeal Cancer?
What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Nasopharyngeal Cancer therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Nasopharyngeal Cancer and their status?
What are the key designations that have been granted to the emerging drugs?
Akeso Pharmaceuticals, Inc.
Betta Pharmaceuticals Co., Ltd.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hoffman La Roche
Jiangsu HengRui Medicine Co., Ltd.
Merck Sharp & Dohme Corp.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/vfoaox
View source version on businesswire.com: https://www.businesswire.com/news/home/20210513005435/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900